Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles OCIOs: U.S. Stocks Are Expensive, But Don’t Trim Yet James Comtois Premium Biopharma Specialist Cormorant Plans New $125 Million Blank-Check Venture Stephen Taub The Investment Landscape of Data Centers: Opportunities for Investors Sponsored by Principal